drugset / Trial / NCT05659602

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

NCT05659602

Completed 111 enrolled Beijing Ditan Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the preliminary efficacy and safety of HH-120 nasal spray in the treatment of asymptomatic or mild COVID-19.

Timeline

Start
2022-07-09
Primary completion
2023-01-03
Completion
2023-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HH-120 Protein / enzyme biologic Intranasal

Indications